Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Oct;40(4):548–556. doi: 10.1038/bjc.1979.220

A radioimmunoassay for cytosine arabinoside.

E M Piall, G W Aherne, V M Marks
PMCID: PMC2010074  PMID: 574019

Abstract

A radioimmunoassay (RIA) for cytosine arabinoside (AraC) has been developed using antiserum raised in a sheep to an AraC monophosphate-ovalbumin conjugate. The antibody shows only 0.008% cross-reactivity with uracil arabinoside (AraU) and low (0.023%) cross-reactivity with other commonly co-administered drugs such as cytotoxic and antibacterial agents, and also a number of naturally occurring nucleosides and nucleotides. It does however cross-react by 125% with AraC monophosphate and by 109% with AraC triphosphate. As little as 1 ng/ml of AraC can be detected in plasma, serum, urine and cerebrospinal fluid (CSF) with no need for prior extraction. This RIA has been used to follow the disappearance of AraC from the plasma of patients receiving the drug.

Full text

PDF
548

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aherne G. W., Piall E. M., Marks V. Development and application of a radioimmunoassay for methotrexate. Br J Cancer. 1977 Nov;36(5):608–617. doi: 10.1038/bjc.1977.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bach M. K. Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-beta-D-arabinofuranosylcytosine (Cytarabine). Cancer Res. 1969 May;29(5):1036–1044. [PubMed] [Google Scholar]
  3. Boutagy J., Harvey D. J. Determination of cytosine arabinoside in human plasma by gas chromatography with a nitrogen-sensitive detector and by gas chromatography--mass spectrometry. J Chromatogr. 1978 Sep 1;146(2):283–296. doi: 10.1016/s0378-4347(00)81894-0. [DOI] [PubMed] [Google Scholar]
  4. CHU M. Y., FISCHER G. A. COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE. Biochem Pharmacol. 1965 Mar;14:333–341. doi: 10.1016/0006-2952(65)90198-x. [DOI] [PubMed] [Google Scholar]
  5. Dedrick R. L., Forrester D. D., Ho D. H. In vitro-in vivo correlation of drug metabolism--deamination of 1- -D-arabinofuranosylcytosine. Biochem Pharmacol. 1972 Jan;21(1):1–16. doi: 10.1016/0006-2952(72)90245-6. [DOI] [PubMed] [Google Scholar]
  6. Furth J. J., Cohen S. S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-beta-d-arabinofuranosylcytosine and the 5'-triphosphate of 9-beta-d-arabinofuranoxyladenine. Cancer Res. 1968 Oct;28(10):2061–2067. [PubMed] [Google Scholar]
  7. Halloran M. J., Parker C. W. The preparation of nucleotide-protein conjugates: carbodiimides as coupling agents. J Immunol. 1966 Mar;96(3):373–378. [PubMed] [Google Scholar]
  8. Hanka L. J. Microbiological assay for cytosine arabinoside (NSC-63878) in biologic materials containing other antitumor or antibacterial drugs. Cancer Chemother Rep. 1971 Dec;55(5):557–560. [PubMed] [Google Scholar]
  9. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  10. Kreis W., Gordon C., Gizoni C., Woodcock T. Extraction and analytic procedures for cytosine arabinoside and 1-beta-D-arabinofuranosyluracil and their 5'-mono-, di-, and tri-phosphates. Cancer Treat Rep. 1977 Jul;61(4):643–646. [PubMed] [Google Scholar]
  11. Meyers R., Malathi V. G., Cox R. P., Silber R. Studies on nucleoside deaminase. Increase in activity in HeLa cell cultures caused by cytosine arabinoside. J Biol Chem. 1973 Sep 10;248(17):5909–5913. [PubMed] [Google Scholar]
  12. Momparler R. L., Chu M. Y., Fischer G. A. Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta. 1968 Jul 23;161(2):481–493. doi: 10.1016/0005-2787(68)90124-x. [DOI] [PubMed] [Google Scholar]
  13. Momparler R. L., Labitan A., Rossi M. Enzymatic estimation and metabolism of 1- -D-arabinofuranosylcytosine in man. Cancer Res. 1972 Feb;32(2):408–412. [PubMed] [Google Scholar]
  14. Notari R. E. A mechanism for the hydrolytic deamination of cytosine arabinoside in aqueous buffer. J Pharm Sci. 1967 Jul;56(7):804–809. doi: 10.1002/jps.2600560703. [DOI] [PubMed] [Google Scholar]
  15. Okabayashi T., Mihara S., Repke D. B., Moffatt J. G. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1977 Feb;37(2):619–624. [PubMed] [Google Scholar]
  16. Robinson J. D., Morris B. A., Marks V. Development of a radioimmunoassay for etorphine (preliminary communication). Res Commun Chem Pathol Pharmacol. 1975 Jan;10(1):1–8. [PubMed] [Google Scholar]
  17. Steuart C. D., Burke P. J. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol. 1971 Sep 22;233(38):109–110. doi: 10.1038/newbio233109a0. [DOI] [PubMed] [Google Scholar]
  18. Tattersall M. H., Ganeshaguru K., Hoffbrand A. V. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol. 1974 May;27(1):39–46. doi: 10.1111/j.1365-2141.1974.tb06772.x. [DOI] [PubMed] [Google Scholar]
  19. Teale J. D., Clough J. M., Marks V. Radioimmunoassay of bleomycin in plasma and urine. Br J Cancer. 1977 Jun;35(6):822–827. doi: 10.1038/bjc.1977.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wan S. H., Huffman D. H., Azarnoff D. L., Hoogstraten B., Larsen W. E. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res. 1974 Feb;34(2):392–397. [PubMed] [Google Scholar]
  21. van Prroijen H. C., Vierwinden G., Wessels J., Haanen C. Cytosine arabinoside binding to human plasma proteins. Arch Int Pharmacodyn Ther. 1977 Oct;229(2):199–205. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES